Immix doses first patient in US in its phase 1b/2a trial in patients with advanced solid tumours

This article was originally published here

The expansion of the study to the US builds upon Immix’ results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose

The post Immix doses first patient in US in its phase 1b/2a trial in patients with advanced solid tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply